Summary
GE HealthCare Technologies Inc. (GEHC) reported a 5% increase in total revenues for the third quarter of 2023, reaching $4.82 billion, and a 7% increase for the first nine months, totaling $14.35 billion. This growth was driven by strong performance across most segments, particularly Pharmaceutical Diagnostics (PDx) and Patient Care Solutions (PCS), with notable contributions from supply chain improvements and price increases. Despite revenue growth, net income attributable to GE HealthCare declined by 23% for the quarter and 14% year-to-date, primarily due to a significant increase in interest and other financial charges stemming from new debt issuances and the Term Loan Facility. The company also saw increased operating expenses related to its transition to a standalone entity and planned investments in R&D. Financially, GEHC ended the quarter with $2.42 billion in cash and cash equivalents. The company's long-term borrowings increased to $10.25 billion. While operating income remained stable year-over-year for the nine-month period, the significant increase in interest expenses impacted profitability. The company's guidance and outlook suggest continued revenue growth, but investors should monitor the impact of rising interest costs on net income and the company's ongoing investments in innovation and operational efficiency.
Financial Highlights
49 data points| Revenue | $4.82B |
| Gross Profit | $1.94B |
| R&D Expenses | $322.00M |
| SG&A Expenses | $996.00M |
| Operating Expenses | $1.32B |
| Operating Income | $617.00M |
| Net Income | $375.00M |
| EPS (Basic) | $0.82 |
| EPS (Diluted) | $0.82 |
| Shares Outstanding (Basic) | 455.00M |
| Shares Outstanding (Diluted) | 458.00M |
Key Highlights
- 1Total revenues increased by 5% to $4.82 billion in Q3 2023 and by 7% to $14.35 billion for the first nine months of 2023, driven by broad-based segment growth.
- 2Organic revenue growth was strong at 6% for Q3 and 9% for the nine-month period, indicating solid underlying business performance.
- 3Net income attributable to GE HealthCare decreased by 23% in Q3 and 14% year-to-date, primarily due to higher interest expenses and increased operating costs.
- 4Interest and other financial charges increased significantly, by $136 million in Q3 and $393 million year-to-date, due to new debt obligations.
- 5Operating income remained stable year-over-year for the nine-month period at $1.75 billion, but net income margin compressed due to increased expenses.
- 6The company ended the period with $2.42 billion in cash and cash equivalents, providing a solid liquidity position.
- 7Remaining Performance Obligations (RPO) stood at $14.16 billion as of September 30, 2023, indicating a strong future revenue pipeline, although down slightly from the prior year.